External broker reports(aggregated public sources), CCZ Statton Equities

CCZ Statton Equities

External broker reports(aggregated public sources)

CCZ is a leading Australian stockbroking firm providing stockbroking and wealth generation services to private clients and institutional investors. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Eli Lilly has reported positive results from its Donanemab confirmatory phase 3 study, meeting both primary and secondary endpoints.</li><li>In a trial involving 1,736 participants with early Alzheimer's disease, the drug demonstrated a 35% reduction in clinical cognitive decline compared to a placebo.</li><li>The company is on track to complete its submission to the FDA this quarter.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Eli Lilly has reported positive results from its Donanemab confirmatory phase 3 study, meeting both primary and secondary endpoints.In a trial involving 1,736 participants with early Alzheimer's disease, the drug demonstrated a 35% reduction in clinical cognitive decline compared to a placebo.The company is on track to complete its submission to the FDA this quarter.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cogstate - Donanemab Strikes Second ‘home Run’ for AD Drug Development

<ul><li>CGS provided a Q3’FY23 trading update with group revenue of $10.9m, +18% vs pcp or $30.5m YTD.</li><li>New clinical trial (CT) contract sales have been weaker than in previous quarters, with $3.4m in signings or $30.7m YTD.</li><li>Mgmt. has flagged a slowdown in decision-making and investment from biotechnology companies as a contributing factor in the weaker contract sales.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

CGS provided a Q3’FY23 trading update with group revenue of $10.9m, +18% vs pcp or $30.5m YTD.New clinical trial (CT) contract sales have been weaker than in previous quarters, with $3.4m in signings or $30.7m YTD.Mgmt. has flagged a slowdown in decision-making and investment from biotechnology companies as a contributing factor in the weaker contract sales.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cogstate - Eyes on the Prize Despite a Temporary Sales Slowdown

<ul><li>CGS’s result was largely pre-announced with rev of $19.5m and EBIT -$0.2m. Clinical trial segment rev was $17.1m, -18% vs pcp impacted by c.$3.3m rev deferred to FY24+.</li><li>Healthcare segment contributed $2.2m, flat vs pcp, which reflects the minimum contracted rev from the Eisai Global Agreement.</li><li>1H’FY23 result does not reflect the opportunity and growth prospects for CGS.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

CGS’s result was largely pre-announced with rev of $19.5m and EBIT -$0.2m. Clinical trial segment rev was $17.1m, -18% vs pcp impacted by c.$3.3m rev deferred to FY24+.Healthcare segment contributed $2.2m, flat vs pcp, which reflects the minimum contracted rev from the Eisai Global Agreement.1H’FY23 result does not reflect the opportunity and growth prospects for CGS.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

<ul><li>CGS provided a business and guidance update ahead of interim results scheduled for 28 Feb-23.</li><li>Delayed clinical trials affected 1H'FY23 revenue, resulting in a -12% decrease to $17.1m, with c.$5m of revenue moved to FY24+.</li><li>Additionally, due to a more significant share of fixed costs, this delay in revenue has affected earnings, with PBT expected to breakeven.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

CGS provided a business and guidance update ahead of interim results scheduled for 28 Feb-23.Delayed clinical trials affected 1H'FY23 revenue, resulting in a -12% decrease to $17.1m, with c.$5m of revenue moved to FY24+.Additionally, due to a more significant share of fixed costs, this delay in revenue has affected earnings, with PBT expected to breakeven.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

<ul><li>A commercially successful drug would warrant new funding to expand its applications. Most of the lifetime investment into a drug occurs after first approval.</li><li>These new trials are more frequently phase 3 or 4 studies with larger patient sizes.</li><li>This was the case for multiple sclerosis (MS), with industry experts and management believing this will be no different for Alzheimer's (AD).</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

A commercially successful drug would warrant new funding to expand its applications. Most of the lifetime investment into a drug occurs after first approval.These new trials are more frequently phase 3 or 4 studies with larger patient sizes.This was the case for multiple sclerosis (MS), with industry experts and management believing this will be no different for Alzheimer's (AD).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cogstate - Is History About to Repeat Itself?

Australia

CogState Limited manufactures and distributes diagnostic and therapeutic products associated with neurological disorders and the measurement of cognitive functions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cogstate Ltd (CGS AU)

Cogstate - Donanemab Strikes Second ‘home Run’ for AD Drug Development

Eli Lilly has reported positive results from its Donanemab confirmatory phase 3 study, meeting both primary and secondary endpoints.

CCZ Statton Equities

Cogstate - Eyes on the Prize Despite a Temporary Sales Slowdown

CGS provided a Q3’FY23 trading update with group revenue of $10.9m, +18% vs pcp or $30.5m YTD. New clinical trial (CT) contract sales have been...

CCZ Statton Equities

Cogstate - Remembering What Matters

CGS’s result was largely pre-announced with rev of $19.5m and EBIT -$0.2m. Clinical trial segment rev was $17.1m, -18% vs pcp impacted by c.$3.3m...

CCZ Statton Equities

Cogstate - Down but Not Out

Delayed clinical trials affected 1H'FY23 revenue, resulting in a -12% decrease to $17.1m, with c.$5m of revenue moved to FY24+.

CCZ Statton Equities

Cogstate - Is History About to Repeat Itself?

A commercially successful drug would warrant new funding to expand its applications. Most of the lifetime investment into a drug occurs after first...

CCZ Statton Equities

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)